Eye injection safety checked in indian diabetes patients
NCT ID NCT05511038
Summary
This study aimed to collect more safety information about an approved eye injection (aflibercept) for diabetic macular edema (DME) specifically in Indian patients. DME is a diabetes complication where fluid leaks into the retina, causing vision loss. Over 52 weeks, researchers monitored 100 participants for side effects and changes in their vision after receiving regular injections.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Disha Eye Hospitals
Kolkata, West Bengal, 700120, India
-
Dr. R.P. Centre for Ophthalmic Sciences, AIIMS
New Delhi, National Capital Territory of Delhi, 110029, India
-
L.V. Prasad Eye Institute
Hyderabad, Andhra Pradesh, 500034, India
-
Lotus Eye Hospital and Institute
Coimbatore, Tamil Nadu, 641014, India
-
M & J Western Regional Institute of Ophthalmology
Ahmedabad, Gujarat, 380016, India
-
Medical Research Foundation, Sankara Nethralaya
Chennai, Tamil Nadu, 600006, India
-
Narayana Nethralaya
Bengaluru, Karnataka, 560010, India
-
Post Graduate Institute of Medical Education and Research
Chandigarh, 160012, India
-
Raghudeep Eye Hospital
Ahmedabad, Gujarat, 380052, India
-
Sankara Eye Hospital
Bengaluru, Karnataka, 560037, India
Conditions
Explore the condition pages connected to this study.